# US 2004/0001829 A1 · Methods for selectively stimulating proliferation of T cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001829 A1
- Document ID: US20040001829A1
- Status: Published application
- Kind: A1
- Application number: 10/390,330
- Filed: 2003-03-17
- Published: 2004-01-01
- Earliest claimed: 1988-11-23
- Assignees: The Regents of the University of Michigan; Genetics Institute, Inc.; The United States of America as represented by the Secretary of the Navy
- Inventors: Carl H. June; Craig B. Thompson; Gary J. Nabel; Gary S. Gray; Paul D. Rennert
- Web page: https://patentgrep.com/patent/US20040001829A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/505: {comprising antibodies}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2740/16011: Human Immunodeficiency Virus, HIV
- C12N 2795/14111: Inoviridae
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods for inducing a population of T cells to proliferate by activating the population of T cells and stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule are described. T cell proliferation occurs in the absence of exogenous growth factors or accessory cells. T cell activation is accomplished by stimulating the T cell receptor (TCR)/CD3 complex or the CD2 surface protein. To induce proliferation of an activated population T cells, an accessory molecule on the surface of the T cells, such as CD28, is stimulated with a ligand which binds the accessory molecule. The T cell population expanded by the method of the invention can be genetically transduced and used for immunotherapy or can be used in methods of diagnosis.

## Claims

### Claim 1

A method for inducing a population of T cells to proliferate, comprising:
a) activating a population of T cells; and
b) stimulating an accessory molecule on the surface of the T cells with a ligand which binds the accessory molecule, the activating and stimulating steps thereby inducing proliferation of the T cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the population of T cells is activated by contacting the T cells with an anti-CD3 antibody.

### Claim 3 (depends on 1)

The method of claim 1, wherein the population of T cells is activated by contacting the T cells with an anti-CD2 antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the population of T cells is activated by contacting the T cells with a protein kinase C activator and a calcium ionophore.

### Claim 5 (depends on 1)

The method of claim 1, wherein the accessory molecule is CD28.

### Claim 6 (depends on 5)

The method of claim 5, wherein the ligand is an anti-CD28 antibody.

### Claim 7 (depends on 5)

The method of claim 5, wherein the ligand is a stimulatory form of a natural ligand for CD28.

### Claim 8 (depends on 7)

The method of claim 7, wherein the natural ligand is in soluble form.

### Claim 9 (depends on 7)

The method of claim 7, wherein the natural ligand is immobilized on a solid phase surface.

### Claim 10

A method for stimulating a population of T cells to proliferate, comprising
a) contacting a population of T cells with
(1) a first agent which stimulates a TCR/CD3 complex-associated signal in the T cells; and
(2) a second agent which stimulates an accessory molecule on the surface of the T cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the first agent is an anti-CD3 antibody.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

### Claim 13 (depends on 12)

The method of claim 12, wherein the anti-CD3 antibody is immobilized on a solid phase surface.

### Claim 14 (depends on 10)

The method of claim 10, wherein the accessory molecule is CD28.

### Claim 15 (depends on 14)

The method of claim 14, wherein the second agent is an anti-CD28 antibody.

### Claim 16 (depends on 15)

The method of claim 15, wherein the anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

### Claim 17 (depends on 10)

The method of claim 10, wherein the second agent is a stimulatory form of a natural ligand for CD28.

### Claim 18 (depends on 17)

The method of claim 17, wherein the natural ligand is in soluble form.

### Claim 19 (depends on 17)

The method of claim 17, wherein the natural ligand is immobilized on a solid phase surface.

### Claim 20 (depends on 13)

The method of claim 13, wherein the solid phase surface further comprises a natural ligand for CD28.

### Claim 21 (depends on 11)

The method of claim 11, further comprising:
b) separating the anti-CD3 antibody from the T cells and the second agent;
c) monitoring proliferation of the T cells in response to continuing exposure to the second agent; and
d) restimulating the T cells with the anti-CD3 antibody and the second agent when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

### Claim 22 (depends on 21)

The method of claim 21, further comprising repeating steps (b)-(d) to produce a population of T cells increased in number of from about 100- to about 100,000-fold the original T cell population.

### Claim 23 (depends on 22)

The method of claim 22 wherein the second agent is a stimulatory form of a natural ligand for CD28.

### Claim 24 (depends on 23)

The method of claim 23, wherein the natural ligand is in soluble form.

### Claim 25 (depends on 23)

The method of claim 23, wherein the natural ligand is immobilized on a solid phase surface.

### Claim 26 (depends on 25)

The method of claim 25, wherein the solid phase surface is a cell membrane.

### Claim 27 (depends on 23)

The method of claim 23, wherein the natural ligand is B7-1.

### Claim 28 (depends on 23)

The method of claim 23, wherein the natural ligand is B7-2.

### Claim 29

A method for stimulating a population of CD4+ T cells to proliferate, comprising:
a) obtaining peripheral blood leukocytes from an individual;
b) isolating a population of CD4+ T cells from the peripheral blood leukocytes by negative selection with a combination of antibodies directed to surface markers unique to the cells negatively selected;
c) contacting the population of CD4+ T cells with an anti-CD3 antibody immobilized on a solid phase and a stimulatory form of a natural ligand for CD28, under conditions appropriate for stimulating proliferation of the T cells;
d) separating the anti-CD3 antibody from the T cells and the natural ligand for CD28;
e) monitoring proliferation of the T cells in response to continuing exposure to the natural-ligand for CD28 by examining cell size or determining the level of expression of a cell surface molecule; and
f) restimulating the T cells with the anti-CD3 antibody and the stimulatory form of the natural ligand for CD28 when T cell size has decreased or the level of expression of the cell surface molecule has decreased to induce further proliferation of the T cells.

### Claim 30 (depends on 29)

The method of claim 29, further comprising repeating steps (d)-(f) to produce a population of T cells increased in number of from about 100- to about 100,000-fold the original T cell population.

### Claim 31 (depends on 30)

The method of claim 30, further comprising genetically transducing the T cells and restoring the transduced T cells to an individual.

### Claim 32

A method of treating HIV infection in an individual, comprising:
a) obtaining peripheral blood leukocytes from the individual;
b) isolating a population of CD4+ T cells from the peripheral blood leukocytes by negative selection with a combination of antibodies directed to surface markers unique to the cells negatively selected;
c) contacting the population of CD4+ T cells with an anti-CD3 antibody and a stimulatory form of a natural ligand for CD28, under conditions appropriate for stimulating proliferation of the T cells;
d) separating the anti-CD3 antibody from the T cells and the natural ligand fro CD28;
e) monitoring proliferation of the T cells in response to continuing exposure to the stimulatory form of a natural ligand for CD28 by examining cell size or determining the level of expression of a cell surface molecule;
f) restimulating the T cells with an anti-CD3 antibody when T cell size has decreased or the level of expression of the cell surface molecule has decreased to induce further proliferation of the T cells;
g) repeating steps (d)-(f) to produce a population of CD4+ T cells increased in number of from about 10-to about 1000-fold the original T cell population; and
h) restoring the T cells to the individual.

### Claim 33 (depends on 32)

The method of claim 32, wherein the natural ligand for CD28 is in a soluble form.

### Claim 33 (depends on 32)

The method of claim 32, further comprising rendering the T cells resistant to HIV infection.

### Claim 34 (depends on 32)

The method of claim 32, wherein the natural ligand for CD28 is immobilized on a solid phase surface.

### Claim 34 (depends on 33)

The method of claim 33, wherein the T cells are rendered resistant to HIV infection by contacting the T cells with at least one anti-retroviral agent which inhibits HIV replication or viral production.

### Claim 35 (depends on 33)

The method of claim 33, wherein the T cells are rendered resistant to HIV infection by genetically transducing the T cells to produce molecules which inhibit HIV infection or replication.

### Claim 36 (depends on 29)

The method of claim 29, wherein the peripheral blood leukocytes are obtained from an individual afflicted with an immunodeficiency associated with a genetic defect and the method further comprises genetically transducing the T cells to correct for the defect and restoring the T cells to the individual.

### Claim 37

A method for selectively inducing differentiation of a population of CD4+ T cells into TH1 cells comprising contacting the population of CD4+ T cells with
(1) a first agent which activates T cells; and
(2) an anti-CD28 antibody to selectively stimulate the differentiation of the CD4+ T cells into TH 1 cells.

### Claim 38 (depends on 37)

The method of claim 37, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.

### Claim 39 (depends on 38)

The method of claim 38, wherein the first agent is an anti-CD3 antibody.

### Claim 40 (depends on 39)

The method of claim 39, wherein anti-CD3 antibody is an anti-human CD3 monoclonal antibody.

### Claim 41 (depends on 39)

The method of claim 39, wherein the anti-CD3 antibody is immobilized on a solid phase surface.

### Claim 42 (depends on 37)

The method of claim 37, wherein the first agent is an anti-CD2 antibody.

### Claim 43 (depends on 37)

The method of claim 37, wherein anti-CD28 antibody is an anti-human CD28 monoclonal antibody.

### Claim 44

A method for selectively inducing differentiation of a population of CD4+ T cells into TH2 cells comprising contacting the population of CD4+ T cells with
(1) a first agent which activates T cells; and
(2) a natural ligand for CD28 to selectively stimulate the differentiation of CD4+ T cells into TH42 cells.

### Claim 45 (depends on 44)

The method of claim 44, wherein the natural ligand is in soluble form.

### Claim 46 (depends on 44)

The method of claim 44, wherein the natural ligand is immobilized on a solid phase surface.

### Claim 47 (depends on 46)

The method of claim 46, wherein the solid phase surface is a cell membrane.

### Claim 48 (depends on 44)

The method of claim 44, wherein the natural ligand is B7-1.

### Claim 49 (depends on 44)

The method of claim 44, wherein the natural ligand is B7-2.

### Claim 50

A method for expanding a population of CD4+ T cells to increase the cells in number to about 5 log10 to about 12 log10 fold the original CD4+ T cell population, comprising:
contacting a population of CD4+ T cells with a solid phase surface, the solid phase surface having a first agent which stimulates a TCR/CD3 complex-associated signal in the T cells and a second agent which stimulates CD28 on the surface of the T cell; and
adding IL-2 to the population of CD4+ T cells such that expansion of the population of CD4+ T cells occurs.

### Claim 51 (depends on 50)

The method of claim 50, wherein the first agent is an anti-CD3 antibody.

### Claim 52 (depends on 51)

The method of claim 51, wherein the anti-CD3 antibody is the monoclonal antibody OKT3.

### Claim 53 (depends on 50)

The method of claim 50, wherein the second agent is an anti-CD28 monoclonal antibody.

### Claim 54 (depends on 53)

The method of claim 53, wherein the anti-CD28 antibody is the monoclonal antibody 9.3.

### Claim 55 (depends on 50)

The method of claim 50, wherein the second agent is a stimulatory form of B7-2.

### Claim 56 (depends on 55)

The method of claim 55, wherein the stimulatory form of B7-2 is a B7-2 μg fusion protein.

### Claim 57 (depends on 50)

The method of claim 50, wherein IL-2 is added to the population of CD4+ T cells in amounts sufficient to maintain proliferation of the CD4+ T cells.

### Claim 58 (depends on 50)

The method of claim 50, wherein IL-2 is added to the population of CD4+ T cells from the beginning of the culture and supplemented every other day in amounts sufficient to maintain proliferation of the CD4+ T cells.

### Claim 59 (depends on 50)

The method of claim 50, wherein the CD4+ T cells are from an HIV infected individual.

### Claim 60 (depends on 50)

A method for augmenting the CD4+ T cell population in an individual, comprising
a) obtaining peripheral blood leukocytes from the individual;
b) isolating a population of CD4+ T cells from the peripheral blood leukocytes by negative selection with a combination of antibodies directed to surface markers unique to the cells negatively selected;
c) expanding the population of CD4+ T cells according to claim 50; and
d) restoring the T cells to the individual.

### Claim 61 (depends on 60)

The method of claim 60, wherein the individual is an individual infected with HIV.

### Claim 62 (depends on 60)

The method of claim 60, further comprising genetically transducing the T cells.

### Claim 63

A method for treating an HIV infected individual, comprising
administering to an HIV infected individual a solid phase surface such that treatment occurs, the solid phase surface having a first agent which stimulates a TCR/CD3 complex-associated signal in T cells and a second agent which stimulates CD28 on the surface of T cells.

### Claim 64 (depends on 63)

The method of claim 63, wherein the first agent is an anti-CD3 antibody.

### Claim 65 (depends on 63)

The method of claim 63, wherein the second agent is an anti-CD28 antibody.

### Claim 66 (depends on 63)

The method of claim 63 further comprising administering to the individual an amount of IL-2 sufficient for stimulating proliferation of the CD4+ T cells of the individual.

### Claim 67

A method for treating an HIV infected individual comprising administering to the individual beads comprising anti-CD3 and anti-CD28 antibodies in an amount sufficient to stimulate proliferation of the CD4+ T cells of the individual such that treatment occurs.

### Claim 68 (depends on 67)

The method of claim 67 further comprising administering IL-2 to the individual in an amount sufficient to further stimulate proliferation of the CD4+ T cells of the individual.

### Claim 69 (depends on 50)

A method for preparing a renewable source of CD4+ T cells, comprising expanding a population of CD4+ T cells according to the method of claim 50, storing a portion of the cells under conditions that will not significantly affect their viability and allow for later use making the stored cells a renewable source of CD4+ T cells.

### Claim 70

A method for selectively enriching a population of CD28+ T cells in CD4+ T cells comprising
contacting a population of CD28+ T cells with a solid phase surface such that selective enrichment of a population of CD28+ T cells occurs, the solid phase surface having a first agent which stimulates a TCR/CD3 complex-associated signal in the T cells and a second agent which stimulates CD28 on the surface of the T cells.

### Claim 71 (depends on 70)

The method of claim 70, wherein the first agent is an anti-CD3 antibody.

### Claim 72 (depends on 71)

The method of claim 71, wherein the anti-CD3 antibody is the monoclonal antibody OKT3.

### Claim 73 (depends on 70)

The method of claim 70, wherein the second agent is an anti-CD28 antibody.

### Claim 74 (depends on 73)

The method of claim 73, wherein the anti-CD28 antibody is the monoclonal antibody 9.3.

### Claim 75 (depends on 70)

The method of claim 70, wherein the second agent is a stimulatory form of B7-2.

### Claim 76 (depends on 75)

The method of claim 75, wherein the stimulatory form of B7-2 is a B7-2 μg fusion protein.
